188 related articles for article (PubMed ID: 17420189)
21. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
22. A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System.
Cocoros NM; Fuller CC; Adimadhyam S; Ball R; Brown JS; Dal Pan GJ; Kluberg SA; Lo Re V; Maro JC; Nguyen M; Orr R; Paraoan D; Perlin J; Poland RE; Driscoll MR; Sands K; Toh S; Yih WK; Platt R;
Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):827-837. PubMed ID: 33797815
[TBL] [Abstract][Full Text] [Related]
23. [FDA's new drug approval system].
Ishii A
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
[No Abstract] [Full Text] [Related]
24. Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.
Harpaz R; Haerian K; Chase HS; Friedman C
AMIA Annu Symp Proc; 2010 Nov; 2010():281-5. PubMed ID: 21346985
[TBL] [Abstract][Full Text] [Related]
25. Adverse drug reactions.
Roswell R; Van Diepen LR; Jones JK; Hicks WE
Lancet; 2001 Feb; 357(9255):561-2. PubMed ID: 11229704
[No Abstract] [Full Text] [Related]
26. Where are risk evaluation and mitigation strategies headed?
Johnson PE
Am J Health Syst Pharm; 2010 Sep; 67(18):1511. PubMed ID: 20811027
[No Abstract] [Full Text] [Related]
27. Monitoring and managing adverse drug reactions.
Fincham JE
Am Pharm; 1992 Feb; NS32(2):74-81. PubMed ID: 1546634
[No Abstract] [Full Text] [Related]
28. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
Ball R; Robb M; Anderson SA; Dal Pan G
Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
[TBL] [Abstract][Full Text] [Related]
29. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
30. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
[TBL] [Abstract][Full Text] [Related]
31. Handling adverse event reports.
Rich S
Nursing; 2000 Nov; 30(11):78. PubMed ID: 11111664
[No Abstract] [Full Text] [Related]
32. Making a difference.
Nat Biotechnol; 2009 Apr; 27(4):297. PubMed ID: 19352347
[No Abstract] [Full Text] [Related]
33. Blueprint for a stronger Food and Drug Administration.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
[No Abstract] [Full Text] [Related]
34. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Matthews EJ; Kruhlak NL; Weaver JL; Benz RD; Contrera JF
Curr Drug Discov Technol; 2004 Dec; 1(4):243-54. PubMed ID: 16472241
[TBL] [Abstract][Full Text] [Related]
36. Adverse drug event trigger tool: a practical methodology for measuring medication related harm.
Rozich JD; Haraden CR; Resar RK
Qual Saf Health Care; 2003 Jun; 12(3):194-200. PubMed ID: 12792009
[TBL] [Abstract][Full Text] [Related]
37. Issues related to risk evaluation and mitigation strategies in health-system pharmacy.
Coffey J
Am J Health Syst Pharm; 2010 Sep; 67(18):1512. PubMed ID: 20811028
[No Abstract] [Full Text] [Related]
38. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists.
Stubbings J; Joshi RA; Hoffman JM
Am J Health Syst Pharm; 2010 Sep; 67(18):1547-54. PubMed ID: 20811034
[No Abstract] [Full Text] [Related]
39. Novel algorithms for improved pattern recognition using the US FDA Adverse Event Network Analyzer.
Botsis T; Scott J; Goud R; Toman P; Sutherland A; Ball R
Stud Health Technol Inform; 2014; 205():1178-82. PubMed ID: 25160375
[TBL] [Abstract][Full Text] [Related]
40. Safety concerns at the FDA.
Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
